PARIS--(BUSINESS WIRE)--Neovacs, a biotechnology company developing proprietary immunotherapeutics for autoimmune and chronic diseases, today announced that subject to regulatory consent, it plans to initiate a Phase II study of its TNF-alpha Kinoid later this year in rheumatoid arthritis patients who have failed treatment with at least one TNF-alpha inhibitor. The decision to proceed with the trial was based on an initial review of encouraging data from the company’s Phase I/II study in Crohn’s disease.
